Search

Your search keyword '"Bouchard, Celine"' showing total 78 results
Start Over Author "Bouchard, Celine"
78 results on '"Bouchard, Celine"'

52. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women

Author

Joura, Elmar A, Giuliano, Anna R, Iversen, Ole-Erik, Bouchard, Celine, Mao, Constance, Mehlsen, Jesper, Moreira, Edson D, Ngan, Yuen, Petersen, Lone Kjeld, Lazcano-Ponce, Eduardo, Pitisuttithum, Punnee, Restrepo, Jaime Alberto, Stuart, Gavin, Woelber, Linn, Yang, Yuh Cheng, Cuzick, Jack, Garland, Suzanne M, Huh, Warner, Kjaer, Susanne K, Bautista, Oliver M, Chan, Ivan S F, Chen, Joshua, Gesser, Richard, Moeller, Erin, Ritter, Michael, Vuocolo, Scott, Luxembourg, Alain, Joura, Elmar A, Giuliano, Anna R, Iversen, Ole-Erik, Bouchard, Celine, Mao, Constance, Mehlsen, Jesper, Moreira, Edson D, Ngan, Yuen, Petersen, Lone Kjeld, Lazcano-Ponce, Eduardo, Pitisuttithum, Punnee, Restrepo, Jaime Alberto, Stuart, Gavin, Woelber, Linn, Yang, Yuh Cheng, Cuzick, Jack, Garland, Suzanne M, Huh, Warner, Kjaer, Susanne K, Bautista, Oliver M, Chan, Ivan S F, Chen, Joshua, Gesser, Richard, Moeller, Erin, Ritter, Michael, Vuocolo, Scott, and Luxembourg, Alain

Abstract

BACKGROUND: The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age.METHODS: We performed a randomized, international, double-blind, phase 2b-3 study of the 9vHPV vaccine in 14,215 women. Participants received the 9vHPV vaccine or the qHPV vaccine in a series of three intramuscular injections on day 1 and at months 2 and 6. Serum was collected for analysis of antibody responses. Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervical tissue were obtained and used for HPV DNA testing, and liquid-based cytologic testing (Papanicolaou testing) was performed regularly. Tissue obtained by means of biopsy or as part of definitive therapy (including a loop electrosurgical excision procedure and conization) was tested for HPV.RESULTS: The rate of high-grade cervical, vulvar, or vaginal disease irrespective of HPV type (i.e., disease caused by HPV types included in the 9vHPV vaccine and those not included) in the modified intention-to-treat population (which included participants with and those without prevalent infection or disease) was 14.0 per 1000 person-years in both vaccine groups. The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52, and 58 in a prespecified per-protocol efficacy population (susceptible population) was 0.1 per 1000 person-years in the 9vHPV group and 1.6 per 1000 person-years in the qHPV group (efficacy of the 9vHPV vaccine, 96.7%; 95% confidence interval, 80.9 to 99.8). Antibody responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine. Adverse events related to injection site were more common in the 9vHPV group than in the qHPV group.CONC

Published
2015

53. A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women

Author

Joura, Elmar A., primary, Giuliano, Anna R., additional, Iversen, Ole-Erik, additional, Bouchard, Celine, additional, Mao, Constance, additional, Mehlsen, Jesper, additional, Moreira, Edson D., additional, Ngan, Yuen, additional, Petersen, Lone Kjeld, additional, Lazcano-Ponce, Eduardo, additional, Pitisuttithum, Punnee, additional, Restrepo, Jaime Alberto, additional, Stuart, Gavin, additional, Woelber, Linn, additional, Yang, Yuh Cheng, additional, Cuzick, Jack, additional, Garland, Suzanne M., additional, Huh, Warner, additional, Kjaer, Susanne K., additional, Bautista, Oliver M., additional, Chan, Ivan S. F., additional, Chen, Joshua, additional, Gesser, Richard, additional, Moeller, Erin, additional, Ritter, Michael, additional, Vuocolo, Scott, additional, and Luxembourg, Alain, additional

Published
2015
Full Text
View/download PDF

54. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

Author

Luxembourg, Alain, primary, Brown, Darron, additional, Bouchard, Celine, additional, Giuliano, Anna R, additional, Iversen, Ole-Erik, additional, Joura, Elmar A, additional, Penny, Mary E, additional, Restrepo, Jaime A, additional, Romaguera, Josefina, additional, Maansson, Roger, additional, Moeller, Erin, additional, Ritter, Michael, additional, and Chen, Joshua, additional

Published
2015
Full Text
View/download PDF

55. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis

Author

van Schalkwyk, Julie, primary, Yudin, Mark H., additional, Allen, Victoria, additional, Bouchard, Celine, additional, Boucher, Marc, additional, Boucoiran, Isabelle, additional, Caddy, Sheila, additional, Castillo, Eliana, additional, Kennedy, V. Logan, additional, Money, Deborah M., additional, Murphy, Kellie, additional, Ogilvie, Gina, additional, Paquet, Caroline, additional, and van Schalkwyk, Julie, additional

Published
2015
Full Text
View/download PDF

56. SOGC Committee Opinion on the Management of a Pregnant Woman Exposed to or Infected With Ebola Virus Disease in Canada

Author

Money, Deborah, primary, Yudin, Mark H., additional, Allen, Victoria, additional, Bouchard, Celine, additional, Boucher, Marc, additional, Boucoiran, Isabelle, additional, Caddy, Sheila, additional, Castillo, Eliana, additional, Kennedy, V. Logan, additional, Money, Deborah, additional, Murphy, Kellie, additional, Ogilvie, Gina, additional, Paquet, Caroline, additional, and van Schalkwyk, Julie, additional

Published
2015
Full Text
View/download PDF

57. Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission: Executive Summary

Author

Money, Deborah, primary, Tulloch, Karen, additional, Boucoiran, Isabelle, additional, Caddy, Sheila, additional, Yudin, Mark H., additional, Allen, Victoria, additional, Bouchard, Celine, additional, Boucher, Marc, additional, Castillo, Eliana, additional, Gottlieb, Heather, additional, Kennedy, V. Logan, additional, Money, Deborah, additional, Murphy, Kellie, additional, Ogilvie, Gina, additional, Paquet, Caroline, additional, van Schalkwyk, Julie, additional, Alimenti, Ariane, additional, and Pick, Neora, additional

Published
2014
Full Text
View/download PDF

58. Female Genital Cosmetic Surgery

Author

Shaw, Dorothy, primary, Lefebvre, Guylaine, additional, Bouchard, Celine, additional, Shapiro, Jodi, additional, Blake, Jennifer, additional, Allen, Lisa, additional, Cassell, Krista, additional, Leyland, Nicholas, additional, Wolfman, Wendy, additional, Allaire, Catherine, additional, Awadalla, Alaa, additional, Best, Carolyn, additional, Dunn, Sheila, additional, Heywood, Mark, additional, Lemyre, Madeleine, additional, Marcoux, Violaine, additional, Menard, Chantal, additional, Potestio, Frank, additional, Rittenberg, David, additional, Singh, Sukhbir, additional, Akhtar, Saima, additional, Camire, Bruno, additional, Christilaw, Jan, additional, Corey, Julie, additional, Nelson, Erin, additional, Pierce, Marianne, additional, Robertson, Deborah, additional, and Simmonds, Anne, additional

Published
2013
Full Text
View/download PDF

59. The Prevention of Early-Onset Neonatal Group B Streptococcal Disease

Author

Money, Deborah, primary, Allen, Victoria M., additional, Yudin, Mark H., additional, Bouchard, Celine, additional, Boucher, Marc, additional, Caddy, Sheila, additional, Castillo, Eliana, additional, Money, Deborah, additional, Murphy, Kellie E., additional, Ogilvie, Gina, additional, Paquet, Caroline, additional, Senikas, Vyta, additional, and van Schalkwyk, Julie, additional

Published
2013
Full Text
View/download PDF

60. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE)

Author

Davis, Susan R., primary, Moreau, Michele, additional, Kroll, Robin, additional, Bouchard, Celine, additional, Panay, Nick, additional, Gass, Margery, additional, Braunstein, Glenn D., additional, Hirschberg, Angelica Linden, additional, Rodenberg, Cynthia, additional, Pack, Simon, additional, Koch, Helga, additional, Moufarege, Alain, additional, and Studd, John, additional

Published
2009
Full Text
View/download PDF

62. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women

Author

Shifren, Jan L., primary, Davis, Susan R., additional, Moreau, Michele, additional, Waldbaum, Arthur, additional, Bouchard, Celine, additional, DeRogatis, Leonard, additional, Derzko, Christine, additional, Bearnson, Patricia, additional, Kakos, Norman, additional, O'Neill, Sheila, additional, Levine, Stephen, additional, Wekselman, Kathryn, additional, Buch, Akshay, additional, Rodenberg, Cynthia, additional, and Kroll, Robin, additional

Published
2006
Full Text
View/download PDF

63. Profile of Female Sexual Function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women

Author

McHorney, Colleen A., primary, Rust, John, additional, Golombok, Susan, additional, Davis, Susan, additional, Bouchard, Celine, additional, Brown, Candace, additional, Basson, Rosemary, additional, Sarti, C. Donati, additional, Kuznicki, James, additional, Rodenberg, Cynthia, additional, and Derogatis, Leonard, additional

Published
2004
Full Text
View/download PDF

65. RETIRED: Lignes directrices pour ce qui est des soins à offrir aux femmes enceintes qui vivent avec le VIH et des interventions visant à atténuer la transmission périnatale : Résumé directif

Author

Yudin, Mark H., Allen, Victoria, Bouchard, Céline, Boucher, Marc, Boucoiran, Isabelle, Caddy, Sheila, Castillo, Eliana, Gottlieb, Heather, Kennedy, V. Logan, Money, Deborah, Murphy, Kellie, Ogilvie, Gina, Paquet, Caroline, van Schalkwyk, Julie, Alimenti, Ariane, Pick, Neora, and Tulloch, Karen

Published
2014
Full Text
View/download PDF

70. RETIRED: Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission: Executive Summary

Author

Money, Deborah, Tulloch, Karen, Boucoiran, Isabelle, Caddy, Sheila, Yudin, Mark H., Allen, Victoria, Bouchard, Celine, Boucher, Marc, Boucoiran, Isabelle, Caddy, Sheila, Castillo, Eliana, Gottlieb, Heather, Kennedy, V. Logan, Money, Deborah, Murphy, Kellie, Ogilvie, Gina, Paquet, Caroline, van Schalkwyk, Julie, Alimenti, Ariane, and Pick, Neora

Abstract

This document has been archived because it contains outdated information. It should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines.

Published
2014
Full Text
View/download PDF

73. Towards a Better Recognition of Urogenital Aging

Author

Drutz, Harold, Bachmann, Gloria, Bouchard, Celine, and Morris, Brian

Abstract

Among the medical problems associated with aging in women, urogenital aging may well be the most ignored. It can be defined as a process that produces a complex of symptoms and physical findings, involving the lower urinary and genital tracts and the pelvic floor, relating ta a decline in ovarian function and to aging. The prevalence of urogenital aging increases with increasing years; depending on the defining symptoms used, the condition is present in up ta 40 percent of mature women.

Published
1996
Full Text
View/download PDF

75. Testosterona para mujeres posmenopáusicas con libido baja que no consumen estrógenos.

Author

Davis, Susan R., Moreau, Michele, Kroll, Robin, Bouchard, Celine, Panay, Nick, Gass, Margery, Braunstein, Glenn D., Hirschberg, Angelica Linden, Rodenberg, Cynthia, Pack, Simon, Koch, Helga, Moufarege, Alain, and Studd, John

Subjects
*SEXUAL desire disorders, *THERAPEUTIC use of testosterone, *HORMONE therapy for menopause, *ESTROGEN replacement therapy, *POSTMENOPAUSE
Abstract

Background: The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. Methods: We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 µg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes. Results: At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 µg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs 0.7, p < 0.001) but not in the group receiving 150 µg per day (1.2 episodes, p = 0.11). As compared with placebo, both doses of testosterone were associated with significant increases in desire (300 µg per day, p < 0.001; 150 µg per day, p = 0.04) and decreases in distress (300 µg per day, p < 0.001; 150 µg per day, p = 0.04). The rate of androgenic adverse events --primarily unwanted hair growth-- was higher in the group receiving 300 µg of testosterone per day than in the placebo group (30.0% vs23.1%). Breast cancer was diagnosed in four women who received testosterone (as compared with none who received placebo); one of the four received the diagnosis in the first 4 months of the study period, and one, in retrospect, had symptoms before undergoing randomization. Conclusions: In postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 µg of testosterone per day resulted in a modest but meaningful improvement in sexual function. The long-term effects of testosterone, including effects on the breast, remain uncertain. [ABSTRACT FROM AUTHOR]

Published
2011

77. Enhancing cervical and breast cancer training in Africa with e-learning.

Author

Fokom Domgue J, Dille I, Fry L, Mafoma R, Bouchard C, Ngom D, Ledaga N, Gnangnon F, Diop M, Traore B, Pande M, Kamgno J, Diomande MI, Tebeu PM, Lecuru F, Plante M, Dangou JM, and Shete S

Subjects
Humans, Female, Early Detection of Cancer, Africa epidemiology, South Africa, Breast Neoplasms, Computer-Assisted Instruction, Uterine Cervical Neoplasms prevention & control
Abstract

Competing Interests: We declare no competing interests.

Published
2023
Full Text
View/download PDF

78. The detection and management of vaginal atrophy.

Author

Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, and Papaioannou A

Subjects
Administration, Intravaginal, Administration, Topical, Atrophy, Estrogen Replacement Therapy, Estrogens administration & dosage, Female, Humans, Lubrication, Postmenopause, Quality of Life, Sexual Behavior, Urinary Tract Infections drug therapy, Urinary Tract Infections etiology, Urinary Tract Infections prevention & control, Vaginal Diseases epidemiology, Vaginal Diseases physiopathology, Vagina pathology, Vaginal Diseases diagnosis, Vaginal Diseases therapy
Abstract

Objective: To support the practitioner in the diagnosis of vaginal atrophy and in the management of the related symptoms., Options: The modalities of evaluation range from basic pelvic examination, examination of the vulva, and laboratory tests., Outcomes: A comprehensive approach to the detection of vaginal atrophy and a discussion of available therapeutic and nontherapeutic options., Evidence: Published opinions of experts, supplemented by evidence from clinical trials, where appropriate., Values: The quality of the evidence is rated using the criteria described by the Canadian Task Force on the Periodic Health Examination., Benefits, Harms, and Costs: Diagnosis of vaginal atrophy is often a challenge because women are unwilling to report symptoms, which have the potential to significantly decrease their quality of life. Increased clinical suspicion is the first step in the diagnosis of vaginal atrophy, which will prompt the initiation of safe therapies with proven efficacy., Recommendations: 1. Health-care providers should routinely assess postmenopausal women for the symptoms and signs of vaginal atrophy, a common condition that exerts significant negative effects on quality of life. (III-C) 2. Regular sexual activity should be encouraged to maintain vaginal health. (II-2B)3. Women experiencing recurrent urinary tract infections should be instructed that consumption of pure cranberry-lingonberry juice, rather than cranberry drink, will decrease their risk of urinary tract infections. (I-A) 4. Vaginal moisturizers applied on a regular basis have an efficacy equivalent to local hormone replacement for the treatment of local urogenital symptoms such as vaginal itching, irritation, and dyspareunia, and should be offered to women wishing to avoid use of hormone replacement therapy. (I-A) 5. Women experiencing vaginal atrophy can be offered any of the following effective vaginal estrogen replacement therapies: conjugated equine estrogen cream (I-A), a sustained-release intravaginal estradiol ring (I-A), or a low-dose estradiol tablet (I-A). 6. Although systemic absorption of estrogen can occur with local preparations, there is insufficient data to recommend annual endometrial surveillance in asymptomatic women using local estrogens. (III-C) 7. For menopausal women experiencing recurrent urinary tract infections and who have no contraindication to local hormone replacement, vaginal estrogen therapy should be offered. (I-A).

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results